KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gross Profit: 2009-2025

Historic Gross Profit for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $636.0 million.

  • Biomarin Pharmaceutical's Gross Profit rose 14.13% to $636.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 15.91%. This contributed to the annual value of $2.3 billion for FY2024, which is 20.48% up from last year.
  • Biomarin Pharmaceutical's Gross Profit amounted to $636.0 million in Q3 2025, which was down 5.82% from $675.3 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Gross Profit peaked at $675.3 million during Q2 2025, and registered a low of $305.2 million during Q3 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Gross Profit averaged around $551.4 million, with its median value being $557.3 million (2024).
  • Its Gross Profit has fluctuated over the past 5 years, first decreased by 6.36% in 2021, then spiked by 30.03% in 2023.
  • Biomarin Pharmaceutical's Gross Profit (Quarterly) stood at $330.1 million in 2021, then climbed by 18.43% to $390.9 million in 2022, then skyrocketed by 30.03% to $508.3 million in 2023, then rose by 20.24% to $611.2 million in 2024, then grew by 14.13% to $636.0 million in 2025.
  • Its Gross Profit stands at $636.0 million for Q3 2025, versus $675.3 million for Q2 2025 and $593.6 million for Q1 2025.